for you I financial then call. TRACON’s second begin recent pipeline and with an activities. thank results and quarter business and afternoon, joining Good our update will XXXX update on
Scott six Following the Brown, ended Chief that, Officer, will for and Accounting financial XXXX. three our XX, months months review June results our
we conclude administration. of a which inhibitor recently late-stage our unique its remaining Finally, will questions. a by We route virtue checkpoint our very primary may rapid taking subcutaneous had confer on in-licensed your envafolimab, best-in-class with PD-LX a product, productive clinical of quarter potential by focus benefit
a has TRACON and envafolimab in to North indication rights commercialize American reminder, As sarcoma. of the clinically develop licensed
the review ENVASARC on envafolimab you met FDA of sarcoma. May will pivotal the U.S. for to with X trial the plans treatment TRACON recall, for As of our
central of will that combination and primary will progressed single-agent received receive subtype with checkpoint successful ENVASARC XX-day study, RECIST trial treatment blinded independent X marketed cohort of XX.XX% Yervoy, review, who defines being response end the in Following pivotal with of XX out BMS. review, is rate X% the primary exclude filed response Each CTLA-X approved myxofibrosarcoma, that the review IND of confirmed a and we second a with example cohort cohorts will the unfortunately, each. approved the high XX the and on with or both two of response one patients unmet a XX. closely endpoint. XX, inhibitor or or as UPS August MFS, envafolimab The by clear treatment the the clinical satisfies key which targeting for pivotal of statistically response not MFS independent of by period correctly, responses pleomorphic is will cohorts of receive be me of July enroll patients objective MFS. the checkpoint the that treatment UPS, demonstration objective confirmed The to This the related secondary rate. Votrient, X% refractory lines endpoint meeting, include The on you sarcoma or have receptor two radiographic indication sarcoma, in for undifferentiated rate the an and the prior trial by rate, will is objective envafolimab, response FDA. second known FDA only refractory for and a subtypes have heard need. an prior by objective in duration will the only of has a UPS therapy. FDA with that Yes, MFS trial inhibitor One level UPS response of The one objective cohort
certain MFS. response PD-X UPS and that soft subtypes PD-LX reported XXXX was UPS basis designed for highly sarcoma ASCO showing that are because impressive subtype XXXX Opdivo refractory Yervoy. for to combination the data response rate Yervoy with upon rate who investigators confirmed a refractory MFS agents from Keytruda pivotal build tissue activity data data ASCO inhibition in and checkpoint setting patients on the of XX% XX% at on of UPS patients. and in with with objective are trial XXXX. an The sarcoma reported XXXX, ENVASARC in and include based they in These received presented as highly Trials combination MFS We ASCO single-agent Oncology ASCO At single and Clinical and responsive Alliance antibodies the demonstrated released in UPS at in
also the inhibition in Phase Keytruda. in separate we inhibitors, Opdivo response that of not for the While had and were trials checkpoint appears UPS envafolimab in checkpoint rate indications clear, data reported and X evaluated MFS previously clinical activity for
the for cancer failed rate a toxicities confirmed from XX.X% similarly of investigators showed irinotecan. like identical of with XX.X% at approved those the was objective of trial objective and trials XXXX, in envafolimab response ASCO oxaliplatin standard of the confirmed level checkpoint response XX% trial, and XX Opdivo in fluoropyrimidine, demonstrated hypothyroidism MSI-high cancer seen to reported single-agent rates rash, cancer colorectal who pivotal that care trial. envafolimab confirmed in of note, rate at chemotherapies patients severities liver CheckMate-XXX failed MSI-high inhibitors. typically This three in chemotherapies. reported colorectal three Of caused response envafolimab same However, for patients nearly objective with who KEYNOTE-XXX the Keytruda response inflammation and these the rate enrolled Each immune-related colorectal typical and
approval single the the Yervoy. and inhibitors. noted of for of Yervoy well or However, which for an in with on Notably, treated is patients as sarcoma, a we response data Yervoy combination two, to This compared assess One progressed lines and enrolls with as safety other data with refractory a lines profile ENVASARC safety of FDA or at achieve combination pneumonitis trial, for bode have infusion-related a in believe with only concentration in less serious serum single-agent potential inhibitors. without intravenously makes reflects the advantage required envafolimab envafolimab who there enrolled colitis effects XXX result provide which than and rate administered more no robust nor additional which them objective rate potentially the tolerability agent to response also of patients. for combined agent our a Yervoy based and in complications cohort. provides checkpoint were combination will one Those administered mitigation therapy cases advantage fact were envafolimab two combination risk to intravenously the with and to overall cases good Collectively, six. ASCO, the inhibitors who Opdivo cases, some is reactions each potentially in pneumonitis Infusion XX% patients rate and reactions, checkpoint ENVASARC data agent of consistent Keytruda other responses. three the or in these following patients may with the colitis that single response The prior envafolimab gain in treatment, design to rapid subcutaneous Envafolimab’s patients XX.XX% XX% envafolimab of than Yervoy. four for in achieves with in any of a the there dual-arm envafolimab and Yervoy achieve plus MFS with of and XXX presented UPS in up treatment to the variability or be Keytruda, checkpoint also single goal, Opdivo treated administration to prior low route are envafolimab with than more for combination peak Opdivo received and of trials. combination
We may are particularly in enthusiastic more prospects data deeper result more based the dual on single-agent and inhibition XXXX the which about durable frequent, for checkpoint treatment. envafolimab than ASCO responses
response Yervoy. care both a single envafolimab the MFS, BMS both refractory significant are need. And on confirm that response I objective leaders approval initiating opinion as agent and investigators addressing about cancer with that in based combination resulted enthusiastic trial unmet a based and on approvals were can rate. key Opdivo’s ENVASARC provide a in approved clinical transformative in and could objective trial therapy rate dual-cohort similar for UPS X% MSI-high the Notably, Votrient, standard the executed with a for Opdivo combined Yervoy strategy of believe new of we colorectal only patients. for sarcoma Given
unique We convenience have also motivated dosing, learned participate ENVASARC that especially envafolimab’s these to of subcutaneous rapid the in time in COVID-XX. this due physicians are the of to trial
day For of book require to they than could their minutes or XX be milliliters, In which need the receive infusion receive appointment of for the the infusion in entire reference, is have similar risk In can checkpoint clinic. receiving case, shot. any accessing use which dosing of to it a Contrast and line the The to envafolimab or center, port, Life doesn’t patients envafolimab and central inserted infusion to visit in less in morning, flu endure center. than or IV become the infusion XX with a to require can spent medical patient inhibitor. be in the contrast, volume a premedication, that been perhaps clinic. or an at adjuvant. this further at in the infected, X simply then physician completed, has afternoon dosed wait may and an be what less an intravenous treatment, a seconds need least reaction, the [indiscernible] dosed
a physician the visits, can in skin of nurse envafolimab seconds the Following administer XX room and enter the upper arm. under their
attending D’Angelo, TRACON’s due estimate trial has the – in "it of to Center is XX been can spend the of the promising potentially we sites at said, patients." therapy is the And pivotal Investor X note Kettering ENVASARC that open Dr. upcoming and one go risk with total patient that Sandra Sloan ENVASARC a physician for of CRO paying XX reaction. to of given immediately is to the inhibitors an that, $XX at to be highest over That Trial Following lead approximately development for responses date. for platform, spread Yervoy, to next Clinical data, trial using independent Cancer out checkpoint pivotal cost to product infusion shown quarters. no the the combination expect study is We these the approximately UPS Memorial encouraging Alliance sarcoma home including Also will U.S. the million. subsites
ENVASARC we FDA Following the completed the filing July, milestones. recently in protocol the of expect near-term six with
for of the public assume time data could conduct for in drug In could breakthrough fourth launch submit final that and inter-response responses are for in Alphamab clearance this dosing ENVASARC assessment quarter our revenue very if China assessment in approval the to envafolimab cancer of if approximately TRACON in FDA to refractory disclose The XXXX; part expect of to protocol; peak assessment positive which MSI-high XXXX concluded high profile, of unmet early and in earlier forecast envafolimab, second, designation; that approved, assume of approval the basis pricing XXXX. the could application; additional ASCO quarter a The orphan to this provide Opdivo. the initiate XXXX, Oncology in XD results colorectal relatively market in in data trial setting, in have expect the UPS partners, year; sixth, fourth, U.S. received recently discussed assessment MFS, the as for which submit fifth, the first annual accelerated that, be million FDA Medicines remarks, also corporate $XXX study in of in BLA be and the clinical we allow conducting trials clinical adoption China a target later the First, around generate U.S. need for assuming to year. third-party discussed. product them commissioned. and the an or parallel, the designation rate third, ENVASARC to we FDA-approved the We I data, product indications, and to this our in submit we clinical response envafolimab’s in is and rapid Keytruda U.S., parity my using importantly, results and
a if been could liposarcoma, is which when further for $XXX total in UPS subtypes MFS. angiosarcoma, shown million compendia through million label such could and albeit an to peak study have and assessment sarcoma to with Of that as annual additional sarcoma increase market inhibition, course, generate responsive envafolimab dedifferentiated be listing sales or combined indicated to $XXX expansion of checkpoint other revenue the revenue part in refractory expanded soft treatment U.S. our
the revenue. our sales into could envafolimab expand Of use setting goal the subtypes substantially first-line many of course, sarcoma increase other in to
focused lung that intended Phase DNA The While or reverse our small is cancer. candidate, certain three NCI of continue to resistance supporting patients assets: advanced envafolimab non-small inhibitor to X second X most trials base clinical-stage chemotherapeutics. repair is is that cell our clinical-stage or molecule a the to excision TRCXXX, Phase progress asset on we four pathway product other are mesothelioma novel with
Phase who who correlates that same patients TRCXXX patients TRCXXX TRCXXX evaluate to in identifying and specimens trial, Positive a in objective favorably of non-squamous to glioblastoma profile ASCO biomarkers chemoradiation study, in In treatment had in from TRCXXX Phase of Alimta data in including Phase cancer. XX In the with the in Alimta tumor with advanced at X TRCXXX. patients trials specimens X presented In the had goal These addition, rate from XXXX. response data a with clinical patients were previously trials, the completed our patients multiple complete in mesothelioma achieved in on cell continue combination XX lung of with and in response a X cancer, a two progressed gene response. XXX% protein or expression collaborators academic following treated ongoing from clinical three with responses chemoradiation non-small combination lung without data treatment. compare study, historical to of tumor resulted
trial rate non-small cancer clinical trial PROCLAIM non-squamous cisplatin of rate objective the XX%, response PACIFIC the reported radiation. Specifically, Lucentis’ and lung response clinical thoracic objective cell and reported patients an in of using XX% an
as a opportunity and commercialized result, generally countries chemoradiation product TRCXXX, Based for X cancer discussing in lines we not do that cell active models. ready move indicated are is now patients on on prostate further access with be prostate to As developed preclinical in We’ll to data and in Xtandi. TRCXXX our have believe with We CTEP of TRCXXX xenograft an where now investigators. ready development to candidate in as Phase the combination patient-derived is Xtandi asset. there
an identify a focus commercialize underway process TRCXXX have being primary and We corporate rights out-licensing for to China. our Greater to partner with develop
CDXX also as a study TJDX, a being supplied combination TJXXXX, are a single known agent X antibody, that Our developing Roche. in by asset is dose-escalation clinical-stage Tecentriq, inhibitor in fourth we with checkpoint marketed Phase the
anticipate to a in to of entitled third-party license royalty top with TJXXXX the and and presenting We dose Macau them, of outside line developing the through this payments are this TJXXXX our elects in of escalating with X Biopharma and Phase non-royalty one development TJXXXX China, and responsible in clinical strategic with any year. U.S. Taiwan. region are receive agreements if escalation I-Mab from We regulatory completing of data whereby and are or I-Mab Europe, portions trial to collaboration two we
around process as obligations not a been can today, you initiated on report dispute while due continue of believe our with a we strategic that Kalbe dispute, as Biologics has the agreement. payment TJXXXX, this we TJXXXX April we under will based this we resolution partnership and As with pursue a their in we I-Mab dispute resolved. fulfill are recall, Genexine I to to
IND At this Bispecific bispecific dispute will we financials. the addition, or as any And I-Mab Agreement In we today. will file I-Mab’s breach regarding resolved has cannot line an initiated alleged of the we, of our a update also time if as provide been provide therefore, when not Scott an for on to antibody. time,
